Sažetak
Uvod. Parkes Weber-ov sindrom (PWS) je kompleksna i retka genetska bolest, koja se manifestuje kombinovanim vaskularnim malformacijama, prvenstveno na krvnim sudovima ekstremiteta, mada mogu biti zahvaćeni i krvni sudovi karlice. Izuzetno retko bolest može imati endokranijalnu i spinalnu lokalizaciju. Lečenje takvih bolesnika predstavlja izazov neurohirurškim centrima i zahteva multidisciplinarni pristup. Prikaz bolesnika. Prikazujemo 46-godišnjeg bolesnika, koji je primljen u Urgentni centar zbog spontane subarahnoidne hemoragije (SAH), flakcidne parapareze i urinarne inkontinencije. Bolesniku je prethodno postavljena dijagnoza PWS, a genetskom analizom dokazana je mutacija RASA1 gena. Takođe, bolesnik je imao SAH i bio hospitalizovan pre 26 godina, dok je pre šest godina, zbog višestrukih hilarnih aneurizmi desne renalne arterije i njenih grana, načinjena desnostrana nefrektomija. Urađena je digitalna subtrakciona angiografija endokranijuma, pri čemu nisu otkrivene aneurizmatske dilatacije i arteriovenske malformacije (AVM). Metodom magnetne rezonance nađena je intraduralna AVM na nivou između pršljenova T12 i L3, koja je u potpunosti ispunila duralnu vreću. Nakon konzervativnog lečenja došlo je do značajnog poboljšanja subjektivnog i kliničkog stanja bolesnika. Zaključak. Prema nama dostupnim podacima u referentnoj naučnoj literaturi, ovo je jedini prikaz bolesnika sa PWS sa spinalnom intraduralnom AVM i spontanim SAH bez srčane insuficijencije i sa istorijom prethodne nefrektomije.
Ključne reči
anomalije
dijagnoza
geni
magnetska rezonanca, snimanje
mutacija
rasa1 protein, humani
krvarenje, subarahnoidno
Reference
Banzić I, Branković M, Maksimović Ž, Davidović L, Marković M, Rančić Z. Parkes Weber syndrome-Diagnostic and management paradigms: A systematic review. Phlebology 2017; 32(6): 371–83.
Naganathan S, Tadi P. Klippel-Trenaunay-Weber Syndrome [updated 2023 Apr 14]. In: StatPearls [Internet]. Treasure Is-land (FL): StatPearls Publishing; 2023. [accessed on 2023 Au-gust 25] Available from: https://www.ncbi.nlm.nih.gov/book
s/NBK558989/
Patel R, Durant EJ, Freed R. Parkes-Weber syndrome in the emergency department. BMJ Case Rep 2021; 14(9): e241649.
Iizuka Y, Suzuki M, Komura S, Takada T, Shimoji K. Conus me-dullaris spinal arteriovenous malformation in a patient with Klippel-Trenaunay-Weber syndrome. A case report and review of the literature. Interv Neuroradiol 2008; 14(2): 185–90.
Hackett ML, Anderson CS. Health outcomes 1 year after sub-arachnoid hemorrhage: an international population-based study. The Australian Cooperative Research on Subarachnoid Hemorrhage Study Group. Neurology 2000; 55(5): 658‒62.
de Rooij NK, Rinkel GJ, Dankbaar JW, Frijns CJ. Delayed cere-bral ischemia after subarachnoid hemorrhage: a systematic re-view of clinical, laboratory, and radiological predictors. Stroke 2013; 44(1): 43‒54.
Deoraj S, Moutzouris DA, Bellini MI. Prevalence, Mechanisms, Treatment, and Complications of Hypertension Postliving Kidney Donation. Biomed Res Int 2021; 2021: 5460672.
Dubow J, Fink ME. Impact of hypertension on stroke. Curr Atheroscler Rep 2011; 13(4): 298‒305.
Provencio JJ, Fu X, Siu A, Rasmussen PA, Hazen SL, Ransohoff RM. CSF neutrophils are implicated in the development of vasospasm in subarachnoid hemorrhage. Neurocrit Care 2010; 12(2): 244‒51.
Kasius KM, Frijns CJ, Algra A, Rinkel GJ. Association of platelet and leukocyte counts with delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2010; 29(6): 576‒83.
Al-Mufti F, Amuluru K, Damodara N, Dodson V, Roh D, Agarwal S, et al. Admission neutrophil-lymphocyte ratio predicts delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. J Neurointerv Surg 2019; 11(11): 1135‒40.
Kostić A, Stojanov D, Stefanović I, Novak V, Kostić E, Benedeto-Stojanov D, et al. Complications after angiogram-negative sub-arachnoid haemorrhage: comparative study of pretruncal and nonpretruncal hemorrhage patients. Srp Arh Celok Lek 2012; 140(1‒2): 8‒13.
Marquardt G, Niebauer T, Schick U, Lorenz R. Long term follow up after perimesencephalic subarachnoid haemorrhage. J Neu-rol Neurosurg Psychiatry 2000; 69(1): 127‒30.
Aghayev K, Iqbal SM, Asghar W, Shahmurzada B, Vrionis FD. Advances in CSF shunt devices and their assessment for the treatment of hydrocephalus. Expert Rev Med Devices 2021; 18(9): 865‒73.
Tomei KL. The evolution of cerebrospinal fluid shunts: advances in technology and technique. Pediatr Neurosurg 2017; 52(6): 369‒80.
Del Bigio MR, Di Curzio DL. Nonsurgical therapy for hydro-cephalus: a comprehensive and critical review. Fluids Barriers CNS 2016; 13: 3.
Kramer AH, Jenne CN, Zygun DA, Roberts DJ, Hill MD, Holodinsky JK, et al. Intraventricular fibrinolysis with tissue plasminogen activator is associated with transient cerebrospi-nal fluid inflammation: a randomized controlled trial. J Cereb Blood Flow Metab 2015; 35(8): 1241–8.
Butnariu LI, Gorduza EV, Florea L, Țarcă E, Moisă ȘM, Trandafir LM, et al. The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms. Int J Mol Sci 2022; 23(20): 12199.